Comment on

• Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate.

  Tenenbaum A, Fisman EZ, Boyko V, Benderly M, Tanne D, Haim M, Matas Z, Motro M, Behar S. Tenenbaum A, et al. Arch Intern Med. 2006 Apr 10;166(7):737-41. doi: 10.1001/archinte.166.7.737. Arch Intern Med. 2006. PMID: 16606809
• Gemfibrozil in the treatment of dyslipidemia: an 18-year mortality follow-up of the Helsinki Heart Study.

  Tenkanen L, Mänttäri M, Kovanen PT, Virkkunen H, Manninen V. Tenkanen L, et al. Arch Intern Med. 2006 Apr 10;166(7):743-8. doi: 10.1001/archinte.166.7.743. Arch Intern Med. 2006. PMID: 16606810